MindCrowd was featured on the front page of the Arizona Republic Living Well section. The story described the project’s goals from the perspective of founder and principal scientist Dr. Matt Huentelman. Ten-Minute Test Aimed at helping Scientists Understand Alzheimer’s Alzheimer’s is the only cause of death among the top 10 (leading causes of death) in […]
This article in the Arizona Republic explains Dr. Huentelman’s vision for MindCrowd and how scientists are going to use the test results to help find a cure for Alzheimer’s. Huentelman, a scientific researcher at Phoenix-based Translational Genomics Research Institute, founded MindCrowd— a mass on scientific study aimed at studying memory in relation to genetics. It’s […]
Mother Nature Network ran a story encouraging the public to take the MindCrowd test to help find a cure for Alzheimer’s. The story includes an interview with Dr. Matt Huentelman, the force behind MindCrowd. Take a quiz, help Alzheimer’s research Wanted: Test scores from 1 million people, as web-based research project aims to learn […]
The TGen researcher explains why he’s using crowd- sourcing to better understand Alzheimer’s disease. In this weekly opinion section of The Arizona Republic, MindCrowd creator Dr. Matt Huentelman explains the MindCrowd project, the promise of genetics, and why MindCrowd will help researchers understand brain function in healthy individuals and provide a base that will help show […]
Christina Estes of KTAR radio discusses how MindCrowd is loing for 1 million people. 1 million sought for Alzheimer’s study – KTAR.com Researchers are loing for one million participants to take a survey as part of an Alzheimer’s study. MindCrowd is the first research project to study millions of people by harnessing the power of […]
“Before we can discover new treatments for brain-related diseases such as Alzheimer’s and Parkinson’s, we need to understand the human genetic blue – DNA – that determines how the brain works in healthy individuals,” he said. “Then we will be better equipped to develop new medicines and therapies for individuals with brain disorders.” Matt Huentelman, […]